Drug Use Investigation for PAXIL Tablet

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Mental Disorders

Treatments: Drug: Paroxetine

Study type: Observational

Funder types: Industry

Identifiers

NCT01371435

112301

Details and patient eligibility

About

This post-marketing surveillance study is designed to detect adverse events (particularly clinically significant adverse drug reactions) occurring in clinical settings and to examine factors likely to affect the safety and efficacy of paroxetine.

Enrollment: 3,708 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with depression/depressed state or panic disorder

Exclusion criteria

• Patients who had been taking PAXIL since before the start of the survey
• Patients with hypersensitivity to paroxetine
• Patients taking monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping treatment with MAOIs
• Concomitant use in patients taking pimozide

Trial design

3,708 participants in 1 patient group

Patients prescribed PAXIL

Description:

Patients with depression/depressed state or panic disorder prescribed PAXIL during study period

Treatment:

Drug: Paroxetine